



# VacZine Analytics

Bringing life to vaccine strategy...

## DiseaseINFOPACK

*Chlamydia trachomatis*

May 2008

## Abstract

**DiseaseINFOPACK: Chlamydia trachomatis**

**CAT No: VADIP008, published June 2008**

### **REPORT ABSTRACT:**

Chlamydia trachomatis is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age.

This **DiseaseINFOPACK** report is an expert review of the current literature regarding Chlamydia trachomatis. Particular emphasis has been placed on proprietary calculations of global incidence and prevalence based on available literature and “in-house” methodology. Key issues and challenges with regard to developing an effective prophylactic vaccine are also noted.

**PAGES: 50**

## Table of contents

Executive summary	Global Incidence
Executive summary (cont...)	US Incidence
Authors Note	UK Incidence
The Pathogen	Reasons for Continuing Increase
Serovars	Cases by Age and Sex (US)
Clinical Features	Cases by Age and Sex (UK)
Pathogenesis	Reasons for Gender Difference
Host Response	US Prevalence
Transmission	US Prevalence (sex, age group - 2007)
Risk Factors	UK Prevalence (sex, age group - 2007)
Prevention and Control	Prevalence: Selected Countries
Diagnosis	Gardasil Registration Studies
Treatment	Regional Prevalence
Morbidity	Calculation of Regional Prevalence
Morbidity (cont.)	Comments on Data Accuracy
Pelvic Inflammatory Disease	Key Issues and Challenges
Pelvic Inflammatory Disease - Incidence	Opportunities for New Treatments
Natural History of Infection	Appendix I – Bibliography
	Appendix II – About VacZine Analytics

## Bibliography

1. Jalal, H., et al. Molecular epidemiology of genital human papillomavirus and *Chlamydia trachomatis* among patients attending a genitourinary medicine clinic - will vaccines protect?. International Journal of STD & AIDS, Volume 18, Number 9, September 2007, pp. 617-621(5)
2. Suchland R.J., et al. Longitudinal assessment of infecting serovars of *Chlamydia trachomatis* in Seattle public health clinics: 1988-1996. Sexually Transmitted Diseases. 2003; 30(4): 357-361.
3. Takahashi S., et al. Longitudinal epidemiology of *Chlamydia trachomatis* serovars in female patients in Japan. Jpn. J. Inf. Dis. 2007; 60: 374-376.
4. Gao X., et al. Distribution study of *Chlamydia trachomatis* serovars among high-risk women in China performed using PCR-restriction fragment length polymorphism genotyping. J Clin Microbiol. 2007; Apr 45(4):1185-9
5. Nogales MC., et al [Diagnosis of *Chlamydia trachomatis* infection in a clinic for sexually transmitted disease: evaluation of cervical, urethral and rectal swab samples by polymerase chain reaction] Enferm Infecc Microbiol Clin. 2007; Jan 25(1):11-5.
6. McKay L., et al. Genital *Chlamydia trachomatis* infection in a subgroup of young men in the UK. Lancet 2003; May 24:361(9371):1792. US Centers for Disease Control and Prevention (CDC). Chlamydia - CDC Fact Sheet. www.cdc.gov. Accessed May 2008.
7. Geisler WM., et al. Pelvic examination findings and Chlamydia trachomatis infection in asymptomatic young women screened with a nucleic acid amplification test. Sex Transm Dis. 2007; Jun 34(6): 335-8.
8. Zdrodowska-Stefanow B. The immunology of *Chlamydia trachomatis*. Arch Immunol Ther Exp (Warsz). 2003; 51(5): 89-94.
9. Loomis WP., et al. *Chlamydia trachomatis* infection alters the development of memory CD8+ T cells. J Immunol. 2006; Sep 15 177(6): 4021-7.
10. Sheffield JS., et al. Spontaneous resolution of asymptomatic *Chlamydia trachomatis* in pregnancy. Obstet Gynecol. 2005; Mar 105(3): 557-62
11. Geisler WM., et al. The natural history of untreated *Chlamydia trachomatis* infection in the interval between screening and returning for treatment Sex Transm Dis. 2008; Feb 35(2):119-23.
12. Geisler WM., et al. The relationship of serovars to clinical manifestations of urogenital *Chlamydia trachomatis* infection. Sexual Transm Dis 2003;30:160-5.
13. Millman K., et al. Population-based genetic epidemiologic analysis of Chlamydia trachomatis serotypes and lack of association between ompA polymorphisms and clinical phenotypes. Microbes Infect. 2006; Mar 8(3):604-11.
14. Lyons JM., et al *Chlamydia trachomatis* serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model. J Clin Pathol. 2004; Jun 57(6):657-9.
16. Katz BP., et al. Estimation of transmission probabilities for chlamydial infection. In: International symposium on human chlamydial infections. Chlamydia infections: proceeds of the seventh international symposium on human chlamydial infections. New York: Cambridge University Press, 1990:567-70
17. Niccolai LM., et al. Burden of recurrent *Chlamydia trachomatis* infections in young women: further uncovering the "hidden epidemic". Arch Pediatr Adolesc Med. 2007 Mar;161(3):246-51. Ann Intern Med. 2006; Oct 17 145(8):564-72.
18. US Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. www.cdc.gov. Accessed May 2008.
19. Macleod J., et al. Coverage and uptake of systematic postal screening for genital *Chlamydia trachomatis* and prevalence of infection in the United Kingdom general population: cross sectional study. BMJ. 2005; Apr 23 330(7497):940.
20. Lee V., et al. Relationship of cervical ectopy to chlamydia infection in young women. J Fam Plann Reprod Health Care. 2006; Apr;32(2): 104-106.
21. Ethier KA., et al. Adolescent women underestimate their susceptibility to sexually transmitted infections. Sex Transm Infect. 2003;79:408-411
22. Franceschi S., et al. Cervical infection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in women from ten areas in four continents. A cross-sectional study. Sex Transm Dis. 2007; Aug 34(8):563-9.

## Bibliography (cont..)

23. US Preventive Services Task Force. Screening for Chlamydial Infection: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine* Volume 147, 128-134.
24. Brunham RC., et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. *J Infect Dis.* 2005; Nov 15 192(10):1836-44.
26. Toth M., et al. Association between Chlamydia trachomatis and abnormal uterine bleeding. *Am J Reprod Immunol.* 2007; May 57(5):361-6.
27. Ratelle S., et al. Neonatal chlamydial infections in Massachusetts, 1992-1993. *Am J Prev Med.* 1997; May-Jun 13(3):221-4.
28. Darville T., et al. Chlamydia trachomatis infections in neonates and young children. *Semin Pediatr Infect Dis.* 2005; Oct; 16(4):235-44.
29. Motrich RD., et al. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. *J Infect.* 2006; Sep 53(3):175-83.
30. Karinen L. , et al. Association between Chlamydia trachomatis antibodies and subfertility in the Northern Finland Birth Cohort 1966; (NFBC 1966), at the age of 31 years. *Epidemiol Infect.* 2004; Oct;132(5):977-84.
31. Madeleine MM., et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. *Int J Cancer.* 2007; Feb 1;120(3):650-5.
32. Silins I., et al. Chlamydia trachomatis infection and persistence of human Papillomavirus. *Int J Cancer.* 2005; Aug 10 116(1):110-5.
33. Simms I. , et al. Risk factors associated with pelvic inflammatory disease. *Sex Transm Infect.* 2006; Dec 82(6):452-7.
34. Wiesenfeld HC. , et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. *Obstet Gynecol.* 200;2 Sep 100(3):456-63.
35. Risser WL., et al. Impact of new diagnostic criteria on the prevalence and incidence of pelvic inflammatory disease. *J Pediatr Adolesc Gynecol.* 2004; Feb 17(1):39-44.
36. UK Health Protection Agency (HPA). Genital chlamydia. Accessed 7 May, 2008.
37. Low N., et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. *Sex Transm Infect.* 2006; Jun 82(3):212-8.
38. Simms I. , et al. Estimates of complications associated with Chlamydia trachomatis need to be refined. Electronic letter, *BMJ*, 26 June 2006.
39. Simms I. , et al. Has the incidence of pelvic inflammatory disease following chlamydial infection been overestimated? *Int J STD AIDS*, April 1, 2008; 19(4): 285 – 286
40. Sutton MY., et al. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. *Sex Transm Dis.* 2005; Dec 32(12):778-84.
41. US Centers for Disease Control and Prevention. (CDC). STD Surveillance Report, 2006
42. US Centers for Disease Control and Prevention (CDC). STD Surveillance Report, 2006
43. WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: World Health Organization, 2001
44. Weinstock H, et al. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. *Perspectives on Sexual and Reproductive Health* 2004;36( 1):6-10.
45. Health Protection Agency. STIs Annual Data 1997-2006 - Data Tables. Accessed 7 May, 2008.
46. UK Health Protection Agency (HPA). STIs Annual Data 1997-2006 - Slide set. Accessed 7 May, 2008.
47. Datta SD., et al. Gonorrhoea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. *Ann Intern Med.* 2007; Jul 17 147(2):89-96.
48. Forhan S. , et al. Prevalence of Sexually Transmitted Infections and Bacterial Vaginosis among Female Adolescents in the United States: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004. 2008 National STD Prevention Conference.
49. Population Division, U.S. Census Bureau. Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States, 2007. Accessed May, 2008.
50. Office for National Statistics. Table 1: Mid-2006 Population Estimates: United Kingdom; estimated resident population by single year of age and sex. Accessed May 2008.
51. Low N. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. *Health Technol Assess.* 2007 Mar 11(8):iii-iv, ix-xii, 1-165.


## Bibliography (cont..)

52. Shields SA. , et al. Prevalence and correlates of Chlamydia infection in Canadian street youth. *J Adolesc Health*. 2004; May;34(5):384--90.
53. Andersen B. , et al. Opportunistic screening of young men for urogenital Chlamydia trachomatis infection in general practice. *Sex Transm Infect*. 2004; Oct 80(5):349-53.
54. Institut de veille sanitaire. Special issue - Chlamydia trachomatis: Prevalence studies in health facilities providing preventive medicine. *Weekly Epidemiology Bulletin*, 3 October 2006 / n° 37-38
55. Stock C., et al. Sexual behavior and the prevalence of Chlamydia trachomatis infection in asymptomatic students in Germany and Spain. *Eur J Epidemiol*. 2001;17(4):385-90.
56. Van Bergen J., et al. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. *Sex Transm Infect*. 2005; Feb 81(1):17-23.
57. Powell J., et al. Chlamydia trachomatis prevalence in men in the mid-west of Ireland. *Sex Transm Infect*. 2004 Oct 80(5):349-53.
58. Keegan H., et al. Chlamydia trachomatis detection in cervical PreservCyt specimens from an Irish urban female population. *Cytopathology*. 2007; Dec 18
59. Latino MA., et al. Prevalence and risk factors for Chlamydia trachomatis infection in young women in North-West of Italy. *Minerva Ginecol*. 2008; Feb 60(1):29-37
60. Vall-Mayans M. et al. Sexually transmitted Chlamydia trachomatis, Neisseria gonorrhoeae, and HIV-1 infections in two at-risk populations in Barcelona: female street prostitutes and STI clinic attendees. *Int J Infect Dis*. 2007; Mar 11(2):115-22
61. Imai H. Prevalence and risk factors of asymptomatic chlamydial infection among students in Japan. *Int J STD AIDS*. 2004; Jun 15(6):408-14.
62. Vaccines and Related Biological Products. Advisory Committee Meeting, May 18, 2006
63. Schillinger JA. Prevalence of Chlamydia trachomatis infection among men screened in 4 U.S. cities. *Sex Transm Dis*. 2005; Feb 32(2):74-7.



## About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high quality-disease and commercial analysis to those working within or in collaboration with the vaccine industry.

-  With our product lines:
  - DiseaseINFOPACK
  - OpportunitySCAN
  - MarketVIEW
  - ExpertREACT
  - VaccineSTATS

Our key focus is helping clients to build the case for developing new vaccines.

# Disclaimer

## All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.





# VacZine Analytics

Bringing life to vaccine strategy...

[www.vacZine-analytics.com](http://www.vacZine-analytics.com)

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)